PMID- 21374666
OWN - NLM
STAT- MEDLINE
DCOM- 20110512
LR  - 20240109
IS  - 1527-3350 (Electronic)
IS  - 0270-9139 (Print)
IS  - 0270-9139 (Linking)
VI  - 53
IP  - 3
DP  - 2011 Mar
TI  - Management of hepatocellular carcinoma: an update.
PG  - 1020-2
LID - 10.1002/hep.24199 [doi]
FAU - Bruix, Jordi
AU  - Bruix J
AD  - Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clinic, 
      University of Barcelona, Barcelona, Spain. bruix@ub.edu
FAU - Sherman, Morris
AU  - Sherman M
CN  - American Association for the Study of Liver Diseases
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
PL  - United States
TA  - Hepatology
JT  - Hepatology (Baltimore, Md.)
JID - 8302946
RN  - 0 (Benzenesulfonates)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Pyridines)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
CIN - Hepatology. 2011 Mar;53(3):1060-1; author reply 1061-2. PMID: 21374678
CIN - Hepatology. 2011 Sep 2;54(3):1113. PMID: 21520202
CIN - Hepatology. 2011 Oct;54(4):1489-90. PMID: 21618569
MH  - Benzenesulfonates/therapeutic use
MH  - Carcinoma, Hepatocellular/diagnostic imaging/*therapy
MH  - Chemoembolization, Therapeutic
MH  - Hepatitis B/complications
MH  - Hepatitis C/complications
MH  - Hepatitis, Autoimmune/complications
MH  - Humans
MH  - Liver Neoplasms/diagnostic imaging/*therapy
MH  - Mass Screening
MH  - Niacinamide/analogs & derivatives
MH  - Phenylurea Compounds
MH  - Pyridines/therapeutic use
MH  - Sorafenib
MH  - Ultrasonography
PMC - PMC3084991
EDAT- 2011/03/05 06:00
MHDA- 2011/05/13 06:00
CRDT- 2011/03/05 06:00
PHST- 2011/03/05 06:00 [entrez]
PHST- 2011/03/05 06:00 [pubmed]
PHST- 2011/05/13 06:00 [medline]
AID - 10.1002/hep.24199 [doi]
PST - ppublish
SO  - Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199.